CFB
BPMC

Cullen/Frost Bankers’s Blueprint Medicines BPMC Stock Holding History

Cullen/Frost Bankers’s Portfolio BPMC Stock Details BPMC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-70
Closed -$8.97K – 1349
2025
Q2 		$8.97K Hold
70
– – ﹤0.01% 1044
2025
Q1 		$6.2K Hold
70
– – ﹤0.01% 1015
2024
Q4 		$6.11K Hold
70
– – ﹤0.01% 964
2024
Q3 		$6.47K Buy
70
+64
+1,067% +$6.36K ﹤0.01% 953
2024
Q2 		$647 Buy
+6
New +$601 ﹤0.01% 1201

Other funds holding BPMC

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return
VanEck Associates
VanEck Associates New York $133B AUM 72.99% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Cullen/Frost Bankers's BPMC Position: Q3 2025 in Review

Cullen/Frost Bankers sold out of Blueprint Medicines (BPMC) in Q3 2025, closing a stake of 70 shares — an estimated $8.97K sold.

Cullen/Frost Bankers first reported a position in BPMC in Q2 2024 and held it in 5 quarters. The position peaked at $8.97K in Q2 2025. 5 funds tracked by Wall St. Rank hold BPMC as of Q3 2025.

  • Cullen/Frost Bankers reported no remaining Blueprint Medicines position as of Q3 2025 after selling out during the quarter.
  • Cullen/Frost Bankers sold 70 Blueprint Medicines shares in Q3 2025, an estimated $8.97K.
  • Cullen/Frost Bankers first reported a position in Blueprint Medicines in Q2 2024 and held it in 5 quarters.
  • Cullen/Frost Bankers's Blueprint Medicines position peaked at $8.97K in Q2 2025.
  • 5 funds tracked by Wall St. Rank held Blueprint Medicines as of Q3 2025.

Based on Cullen/Frost Bankers's 13F filing for Q3 2025, filed 31 Oct 2025.